logo

For the Inventor, By the Inventor

Nuremberg, Germany

Kurt H Ahrens

This inventor holds 26 USPTO granted patents, plus 4 CIPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Ludwig Heumann & Co. Gmbh, Heumann Pharma Gmbh & Co.. Active years: 1978-1991.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kurt H Ahrens. Retrieved from https://idiyas.com/inventor/kurt-h-ahrens

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 26

% Patents Active = 100.0

 

Average Co-Inventor Count = 4.5

ph-index = 5

Forward Citations = 166(Granted Patents)


Location History:

  • Schwaig, DE (1978)
  • Nurnberg, DE (1987 - 1990)
  • Nuremberg, DE (1985 - 1991)

Company Filing History:

goldMedal15 out of 23 
 
Ludwig Heumann & Co. Gmbh
 patents
silverMedal11 out of 17 
 
Heumann Pharma Gmbh & Co.
 patents

Years Active: 1978-1991

Loading Chart...
Loading Chart...
Areas of Expertise:
Benzimidazoles
Pyrimidine Derivatives
Imidazolyl Compounds
Dihydropyridazinone
Thiadiazole Derivatives
Benzothiazole
Diazole Compounds
Pyrazole Derivatives
Quinazoline
Antispasmodic Agents
Alkanol Derivatives
Pharmaceutical Preparations
26 patents (USPTO):Explore Patents
1. 5039675 - Benzimidazoles and pharmaceutical preparations containing these compounds (1991-08-13),
2. 5025016 - Pyrimidine-thioalkyl pyridine derivatives, medicaments containing these (1991-06-18),
3. 5021431 - Imidazolyl alkyl guanidine derivatives, processes for their preparation (1991-06-04),
4. 4978773 - Process for the preparation of 2,6-dichlorodiphenylaminoacetic acid (1990-12-18),
5. 4973755 - Stable solvent adducts of (1990-11-27),
6. 4968808 - Process for the preparation of nitroethene derivatives (1990-11-06),
7. 4968683 - 6-oxo-pyridazine derivatives, a process for their preparation and (1990-11-06),
8. 4957920 - Benzimidazoles, and pharmaceutical preparations containing these (1990-09-18),
9. 4921856 - Dihydropyridazinone derivatives, a process for their preparation and (1990-05-01),
10. 4833141 - 4-[4-[[2-(halophenyl)-2-[1H-tr:azol(or (1989-05-23),
11. 4816455 - Crystalline, anhydrous sigma-form of (1989-03-28),
12. 4757080 - 1,4-dihydropyridine derivatives (1988-07-12),
13. 4738960 - 1,3,4-Thiadiazole derivatives and pharmaceutical preparations useful as (1988-04-19),
14. 4732986 - Benzothiazole derivatives, processes for their preparation and (1988-03-22),
15. 4727081 - 3,4-Diazole derivatives and pharmaceutical preparations containing these (1988-02-23),

Title: The Innovations of Kurt H. Ahrens: A Pioneer in Pharmaceutical Patents

Introduction: Kurt H. Ahrens, based in Nuremberg, Germany, is a distinguished inventor recognized for his significant contributions to the field of pharmaceuticals. With an impressive portfolio of 26 patents, Ahrens has been instrumental in developing novel compounds that have positive implications for healthcare.

Latest Patents: Among his recent innovations, Ahrens has focused on benzimidazoles and pharmaceutical preparations containing these compounds. His patent describes new benzimidazoles characterized by their unique chemical structure, where the pyridazinone ring is attached to the benzimidazole ring, with various alkyl groups and functional substitutions. These compounds have been identified as effective and positive inotropic substances, providing alternative therapeutic avenues that operate independently of phosphodiesterase inhibition. Another notable patent involves the creation of pyrimidine-thioalkyl pyridine derivatives, showcasing his versatility and commitment to advancing medicinal chemistry. These derivatives have potential applications in developing new medicaments, emphasizing Ahrens’s impact on treatment options in modern medicine.

Career Highlights: Kurt H. Ahrens has built a robust career in pharmaceutical innovation, with significant tenures at prominent companies such as Ludwig Heumann & Co. GmbH and Heumann Pharma GmbH & Co. His work at these institutions has facilitated numerous discoveries that address unmet medical needs, enhancing treatment efficacy and patient outcomes.

Collaborations: Ahrens's career has also been marked by fruitful collaborations with esteemed colleagues, including Helmut Schickaneder and Peter Morsdorf. These partnerships have likely contributed to the depth and success of Ahrens's research, fostering an environment of shared knowledge and innovation in the pharmaceutical domain.

Conclusion: Kurt H. Ahrens stands out as a prominent figure in the landscape of pharmaceutical inventions. His extensive patent portfolio and collaborative endeavors underscore his commitment to innovation and improving healthcare outcomes. As his work continues to evolve, Ahrens remains a significant contributor to the field of medicinal chemistry, paving the way for future developments in pharmaceuticals.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…